Symptomatic Genetic Dilated Cardiomyopathy
Cardiovascular
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2026
2027
2028
Kardigandanicamtiv
Clinical Trials (1)
Total enrollment: 332 patients across 1 trials
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
Start: Feb 2026Est. completion: Jan 2028332 patients
Phase 2/3Recruiting
Related Jobs in Cardiovascular
Embedded Software and System Test Engineer (H/F)
Cardiawave
Levallois-Perret, France (Hybrid)
Just now
Territory Sales Manager - Iowa / Nebraska
HeartFlow
Cedar Rapids, IA; Des Moines, IA; Omaha, NE; Lincoln, NE
23h ago
From $150K/yr
Associate Regional Clinical Consultant
Johnson & Johnson
Amersfoort, Utrecht, Netherlands
Yesterday
Medical Affairs Sr Scientist- Electrophysiology
Johnson & Johnson
Irvine, California, United States of America
Yesterday
$92K - $148K/yr
Labeling Operations Specialist
Johnson & Johnson
Danvers, Massachusetts, United States of America
Yesterday
Physician Program Director, Great North
Johnson & Johnson
Danvers, Massachusetts, United States of America
Yesterday
$132K - $212K/yr
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 332 patients
1 companies competing in this space